Dr. Ritesh Gupta

MBBS, MD - General Medicine

Internal Medicine, Sexologist

31 years experience overall

95%
80 patients
Sector 128 Max Super Speciality Hospital, Noida
Prime 
Verified details
1500 fee
Clinic Appointment

Stories

show all stories

About Dr. Ritesh Gupta

Dr. Gupta has authored and co authored various research articles and pread more

Practices at

Address
128, Jaypee Hospital Road, Uttar Pradesh, Landmark : Opposite Delhi Public School
Fees
1500 for regular consultation
Timings
MON 04:00 PM
05:00 PM
TUE 04:00 PM
05:00 PM
View all timings
Photos
This profile is claimed.
know more

services

Type 1 Diabetes Treatment
Thyroid Disorder Treatment
Diabetic foot
Insulin Therapy
Male Sexual Dysfunction & Hormonal Disorder
Insulin Treatment
Peritoneal Dialysis
Arthritis Management
Irritable Bowel Syndrome ( IBS ) Treatment
Congenital Disorders Evaluation / Treatment
Show More services (47)
Common Questions
Q :
Where does Dr. Ritesh Gupta practice?
A :
Dr. Ritesh Gupta practices at Max Super Speciality Hospital, Noida - Sector 128.
Q :
How can I take Dr. Ritesh Gupta's appointment ?
A :
You can take Dr. Ritesh Gupta's appointment online through Practo for in-clinic visit with the doctor.
Q :
Why do patients visit Dr. Ritesh Gupta?
A :
Patients frequently visit Dr. Ritesh Gupta for Type 1 Diabetes Treatment, Thyroid Disorder Treatment, Diabetic foot. To see more reasons visit the doctor's profile on Practo.
Q :
What do patients say about Dr. Ritesh Gupta?
A :
Dr. Ritesh Gupta has been recommended by 76 patients and has recieved stories from 8 patients. You can read detailed patient stories of the doctor on Practo.
Q :
What is Dr. Ritesh Gupta's education qualification?
A :
Dr. Ritesh Gupta has the following qualifications - MBBS, MD - General Medicine. You can book the doctor through the doctor's profile on Practo.

Other Information

Specializations

Internal Medicine
Sexologist
Diabetologist

Education

MBBS - All India Institute of Medical Sciences, New Delhi, 1994
MD - General Medicine - All India Institute of Medical Sciences, New Delhi, 1998

Experience

Additional Director at Fortis C-DOC at Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology
Head Clinical Operations and Senior Consultant at Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology
Consultant in the Department of Diabetes and Metabolic Disease at Fortis Flt Lt Rajan Dhall Hospital, Vasant Kunj
Consultant in Internal Medicine at Apollo Clinic at an initiative of Apollo Health and Lifestyle Limited
Senior Resident in the Department of Cardiology and as Internist at Escorts Heart Institute and Research Centre
Senior Resident (Registrar) in the Department of Medicine at All India Institute of Medical Sciences

Awards and Recognitions

Handa R, Gupta R, Wig N, Agarwal P, Wali JP. Microfilariae of Wuchereria bancrofti in Ascitic Fluid. Indian J Med Sci
Gupta R, Prasad HK, Nagarkar KM, Dey AB. Preliminary study on circulating serum levels of tumor necrosis factor-Alpha in patients of tuberculosis. Indian J Clin Biochem
Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, Joshi SR, Sadikot S, Gupta R, Gulati S, Munjal YP; Consensus Group. Consensus Statement for Diagnosis of Obesity, Abdominal Obesity and the Metabolic Syndrome for Asian India
Gupta R, Misra A. Screening For And Prevention Of Diabetes In India: Need For Simple And Innovative Strategies. Diabetes Technol Ther
Subramanian A, Nigam P, Misra A, Pandey Rn, Mathur M, Gupta R, Madhusudan S. Severe Vitamin D Deficiency In Patients With Type 2 Diabetes In North India
Co-investigator In The Trial Titled Phase 2, 12 Week Randomized, Double Blind, Parallel Group Placebo-controlled Study To Evaluate Safety, Tolerability, And Efficacy Of Grc 8200, A New Oral Dpp-iv Inhibitor, In Patients With Type 2 Diabe
Co-investigator In The Trial Titled Multicenter, Randomized, Double Blind, Placebo-controlled Clinical Trial To Evaluate The Effect Of 52 Weeks Treatment With Vildagliptin On Left Ventricular Function In Patients With Type 2 Diabetes
Co-investigator In The Trial Titled Randomized, Double-blind, Placebo- And Sitagliptin-controlled, Multi-center Study To Evaluate Safety And Efficacy Of Dutogliptin In Type 2 Diabetes Mellitus Subjects With Moderate And Severe Renal Impai
Co-investigator In The Trial Titled 12- Week Multicenter, Randomized, Double Blind, Placebo-controlled Parallel Group Adaptive Design Study To Evaluate The Efficacy On Blood Glucose Control And Safety Of Five Doses Of Lcq
Co-investigator In The Trial Titled Multicentre, Randomized, Double-blind, Placebo-controlled Phase Iv Trial To Evaluate The Effect Of Saxagliptin On The Incidence Of Cardiovascular Death, Myocardial Infarction Or Ischemic Stroke In Patie

Registrations

37990 Delhi Medical Council, 2008